Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.45 |
| ▸ | RORC | P51449 | 4/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.43 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | TACR3 | P29371 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3074806 | 1.00 | MEN1 (0.46) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL18618454 | 0.87 | ALDH1A1 (0.54) | PDE4BMMP13GPR119 | |
| SCHEMBL18255827 | 0.85 | MEN1 (0.49) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL15141289 | 0.84 | ENPP2 (0.51) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL14610186 | 0.84 | ENPP2 (0.51) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL14934468 | 0.84 | ENPP2 (0.51) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL16109014 | 0.84 | ENPP2 (0.51) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL15194668 | 0.83 | HDAC1 (0.51) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL18252871 | 0.82 | TACR1 (0.51) | MEN1KMT2AHDAC1HDAC2RORC | |
| SCHEMBL951494 | 0.82 | TACR1 (0.53) | MEN1KMT2AHDAC1HDAC2RORC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250042855-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY AND GUT-BRAIN AXIS | THE JOHNS HOPKINS UNIVERSITY | 2025-02-06 | — | — | US | disclosed |
| WO-2023102477-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-06-08 | — | — | WO | disclosed |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
| WO-2016187393-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. (US) | 2016-11-24 | — | — | WO | disclosed |
| US-20160340356-A1 | CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2016-11-24 | — | — | US | disclosed |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS, INC. | 2015-07-16 | — | — | US | disclosed |
| US-20140018390-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS, INC. (US) | 2014-01-16 | — | — | US | disclosed |
| US-8450492-B2 | Deuterated benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| EP-1910322-B1 | NOVEL DEUTERATED BENZO [D][1,3]-DIOXOL DERIVATIVES AS SEROTONIN REUPTAKE INHIBITORS | CONCERT PHARMACEUTICALS INC (US) | 2012-09-05 | — | — | EP | disclosed |
| US-20100222589-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. | 2010-09-02 | — | — | US | disclosed |
| US-7678914-B2 | Deuterated benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20080287495-A1 | Novel benzo[d][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. | 2008-11-20 | — | — | US | disclosed |
| US-20080033011-A1 | NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES | CONCERT PHARMACEUTICALS INC. (US) | 2008-02-07 | — | — | US | disclosed |
| US-20070191432-A1 | Novel benzo[D][1,3]-dioxol derivatives | CONCERT PHARMACEUTICALS INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10464934-B2 | Substituted tetrahydropyrans as CCR2 modulators | CCR2, CCR1, CCR5 | MEN1 4868/4885KMT2A 4009/4885HDAC1 508/4885 |
| US-20080033011-A1 | NOVEL BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, TPH2, HTR5A | MEN1 3930/4885KMT2A 4272/4885HDAC1 2638/4885 |
| US-20140018390-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, DRD1 | MEN1 1238/4885KMT2A 4096/4885HDAC1 2068/4885 |
| US-20180086756-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | MEN1 4868/4885KMT2A 4009/4885HDAC1 508/4885 |
| US-20100222589-A1 | DEUTERATED BENZO[D][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, DRD1 | MEN1 1238/4885KMT2A 4096/4885HDAC1 2068/4885 |
| US-20250042855-A1 | PERIPHERALLY AND LUMINALLY-RESTRICTED INHIBITORS OF THE SEROTONIN TRANSPORTER AS TREATMENTS FOR DISORDERS OF GASTROINTESTINAL MOTILITY AND GUT-BRAIN AXIS | SLC6A4, HTR6, HTR5A | MEN1 997/4885KMT2A 3009/4885HDAC1 2208/4885 |
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | MEN1 4868/4885KMT2A 4009/4885HDAC1 508/4885 |
| US-20080287495-A1 | Novel benzo[d][1,3]-dioxol derivatives | TPH1, HTR1D, HTR1A | MEN1 1670/4885KMT2A 4420/4885HDAC1 2568/4885 |
| US-20220153733-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | MEN1 4864/4885KMT2A 4477/4885HDAC1 289/4885 |
| US-20160340356-A1 | CCR2 MODULATORS | CCR2, CCR1, CCR5 | MEN1 4866/4885KMT2A 4246/4885HDAC1 488/4885 |
| US-20070191432-A1 | Novel benzo[D][1,3]-dioxol derivatives | TPH1, HTR1D, HTR1A | MEN1 1670/4885KMT2A 4420/4885HDAC1 2568/4885 |
| US-20150196544-A1 | NOVEL BENZO[d][1,3]-DIOXOL DERIVATIVES | TPH1, HTR1D, HTR1A | MEN1 1670/4885KMT2A 4420/4885HDAC1 2568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.